Company: Axial Biotherapeutics
Job title: Director, Bioanalytical & Biomarker Development
Gregory Preston got his Ph.D. in Biomedical Sciences from the University of Connecticut in 1985. Greg then spent 5 productive years at John’s Hopkins University School of Medicine in Baltimore where he worked with Dr. Peter Agre on the discovery and molecular characterization of the Aquaporin family of membrane water channels. In industry, Greg has worked at several companies with growing responsibilities in the discovery, assay development, qualification, and bioanalysis of biomarkers and biotherapeutics. Greg is currently the Director of Bioanalytical and Biomarker Development at Axial Biotherapeutics in Waltham, MA, a clinical stage company harnessing the gut-brain axis to develop novel CNS therapeutics to improve the quality of life for people with CNS diseases and disorders.